New framework for a non-animal approach adequately assures the safety of cosmetic ingredients - A case study on caffeine.

Caffeine New approach methodologies Next generation risk assessment Physiologically-based kinetic modelling Read-across Systemic toxicity

Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 25 11 2020
revised: 11 03 2021
accepted: 13 04 2021
pubmed: 28 4 2021
medline: 15 12 2021
entrez: 27 4 2021
Statut: ppublish

Résumé

This case study on the model substance caffeine demonstrates the viability of a 10-step read-across (RAX) framework in practice. New approach methodologies (NAM), including RAX and physiologically-based kinetic (PBK) modelling were used to assess the consumer safety of caffeine. Appropriate animal systemic toxicity data were used from the most relevant RAX analogue while assuming that no suitable animal toxicity data were available for caffeine. Based on structural similarities, three primary metabolites of the target chemical caffeine (theophylline, theobromine and paraxanthine) were selected as its most relevant analogues, to estimate a point of departure in order to support a next generation risk assessment (NGRA). On the basis of the pivotal mode of action (MOA) of caffeine and other methylxanthines, theophylline appeared to be the most potent and suitable analogue. A worst-case aggregate exposure assessment determined consumer exposure to caffeine from different sources, such as cosmetics and food/drinks. Using a PBK model to estimate human blood concentrations following exposure to caffeine, an acceptable Margin of Internal Exposure (MOIE) of 27-fold was derived on the basis of a RAX using theophylline animal data, which suggests that the NGRA approach for caffeine is sufficiently conservative to protect human health.

Identifiants

pubmed: 33905778
pii: S0273-2300(21)00071-4
doi: 10.1016/j.yrtph.2021.104931
pii:
doi:

Substances chimiques

Cosmetics 0
Xanthines 0
methylxanthine 28109-92-4
Caffeine 3G6A5W338E
Theophylline C137DTR5RG
Theobromine OBD445WZ5P
1,7-dimethylxanthine Q3565Y41V7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104931

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Dagmar Bury (D)

L'Oréal, Research & Innovation, 9 Rue Pierre Dreyfus, 92110, Clichy, France. Electronic address: dagmar.bury@rd.loreal.com.

Camilla Alexander-White (C)

MKTox & Co Ltd, 36 Fairford Crescent, Downhead Park, Milton Keynes, Buckinghamshire, MK15 9AQ, UK.

Harvey J Clewell (HJ)

Ramboll Health Sciences, 3107 Armand Street, Monroe, LA, 71201, USA.

Mark Cronin (M)

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 AF, UK.

Bertrand Desprez (B)

Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium.

Ann Detroyer (A)

L'Oréal, Research & Innovation, 1 Avenue Eugène Schueller, Aulnay-sous-Bois, France.

Alina Efremenko (A)

ScitoVation, Research Triangle Park, Durham, NC, USA.

James Firman (J)

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 AF, UK.

Eric Hack (E)

ScitoVation, Research Triangle Park, Durham, NC, USA.

Nicola J Hewitt (NJ)

The Procter & Gamble Co., Cincinnati, OH, USA.

Gerry Kenna (G)

Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium.

Martina Klaric (M)

Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium.

Cathy Lester (C)

The Procter & Gamble Co., Cincinnati, OH, USA.

Catherine Mahony (C)

Procter & Gamble Technical Centres Ltd, Reading, RG2 0RX, UK.

Gladys Ouedraogo (G)

L'Oréal, Research & Innovation, 1 Avenue Eugène Schueller, Aulnay-sous-Bois, France.

Alicia Paini (A)

European Commission Joint Research Centre, Ispra, Italy.

Andreas Schepky (A)

Beiersdorf, Unnastrasse 48, 20253, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH